NBC News logo
ARS Technica logo
Washington Examiner logo
9 articles
·1M

Dr. Vinay Prasad Appointed as New Head of FDA's Center for Biologics Evaluation

Dr. Vinay Prasad's appointment as vaccine chief at the FDA raises concerns about future vaccine approvals, amid criticism of the agency's past policies.


Overview

A summary of the key points of this story verified across multiple sources.

Dr. Vinay Prasad has been appointed head of the FDA's Center for Biologics Evaluation and Research, succeeding Dr. Peter Marks. Prasad, known for his controversial critiques of COVID-19 policies, has expressed skepticism about previous vaccine approvals, particularly for children. His appointment has raised investor concerns, with biotech stocks falling following the announcement. Kommissioner Dr. Marty Makary praised Prasad's scientific rigor, but public health experts worry that his views may hinder vaccine approvals. Marks resigned in March amid disagreements with HHS Secretary Robert F. Kennedy Jr. regarding transparency and vaccine safety.

Content generated by AI—learn more or report issue.

Pano Newsletter

Get both sides in 5 minutes with our daily newsletter.

Analysis

Compare how each side frames the story — including which facts they emphasize or leave out.

Prasad's critical stance on COVID-19 vaccine policies and emergency approvals reflects growing concerns about the FDA's oversight of vaccine safety during and after the pandemic.

His questioning of vaccine mandates and suggestions for randomized clinical trials indicate a more cautious approach that may delay future vaccine approvals, thus affecting public confidence in vaccination efforts.

Prasad's historical comparisons and divisive rhetoric have led to criticism from public health experts, raising concerns that his leadership might exacerbate vaccine hesitancy.

Articles (9)

Compare how different news outlets are covering this story.

LeftCenterRight
CNN
NBC News
CBS News
ARS Technica
Associated Press
Washington Examiner
Newsmax
Newsmax
Epoch Times
FDA Taps Covid Booster Critic to Oversee Vaccine Approvals
NewsmaxNewsmax·1M·
Right
This outlet favors right-wing views.

No highlight available for this article.

FDA Taps Covid Booster Critic to Oversee Vaccine Approvals
NewsmaxNewsmax·1M·
Right
This outlet favors right-wing views.

No highlight available for this article.

FAQ

A list of follow-up questions readers often ask about this story.

History

A summary of how this story has evolved over the last 24 hours.

  • 1M
    CNN logo
    Epoch Times logo
    CBS News logo
    6 articles